文献速递泌尿男性生殖肿瘤支持与姑息治疗

ARASENS 研究:达罗他胺联合多西他赛方案中预防性 G-CSF 对多西他赛剂量强度与安全性的影响

Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study.
PubMed 文献 · Eur J Cancer · 2026-01-30

ARASENS III 期研究共纳入 1273 例有 RDI 数据的 mHSPC 患者,比较达罗他胺或安慰剂联合 ADT 和多西他赛时 G-CSF 使用与多西他赛 RDI 的关系。超过 97% 患者接受 RDI>80% 的有效剂量;RDI≤85% 亚组 3 级以上 TEAE 及中性粒细胞减少更常见,但两亚组多西他赛停药率相似。

要点

  • >97% 患者接受多西他赛有效剂量(RDI>80%)。
  • RDI≤85% 亚组 3 级以上中性粒细胞减少和发热性中性粒细胞减少更高。
  • 适当剂量调整和早期 G-CSF 可使几乎所有患者完成有效剂量。

核心结论

  • 适当的多西他赛剂量调整和早期使用 G-CSF 使几乎所有患者在接受达罗他胺联合 ADT 时获得有效多西他赛剂量,并可能预防中性粒细胞减少并发症。

研究设计与样本

  • ARASENS(NCT02799602)为 III 期随机研究,患者随机接受达罗他胺 600 mg 口服每日两次或安慰剂,联合 ADT 和多西他赛。
  • 共 1273 例有 docetaxel RDI 数据的患者纳入分析(达罗他胺 n=637,安慰剂 n=636),按 RDI≤85% 与 >85% 分组分析基线特征、G-CSF 使用和安全性。

主要发现

  • >97% 患者接受多西他赛有效剂量(RDI>80%)。
  • RDI≤85% 患者中 >60% 来自亚太地区。
  • 联合 G-CSF 使用率在达罗他胺组为 42.4%、安慰剂组为 44.6%,主要作为二级预防。
  • 达罗他胺组 61.3%、安慰剂组 64.4% 患者同时接受多西他赛剂量调整和 G-CSF。
  • RDI≤85% 亚组 3 级以上 TEAE、3 级以上中性粒细胞减少和 3 级以上发热性中性粒细胞减少更高。

关键数值与推荐

  • 多西他赛停药率:RDI≤85% 亚组达罗他胺 7.2%、安慰剂 10.8%;RDI>85% 亚组达罗他胺 8.1%、安慰剂 10.5%。
  • 导致多西他赛剂量调整的 TEAE 在 RDI≤85% 亚组更常见:达罗他胺 92.8%、安慰剂 97.3%,而 RDI>85% 亚组分别为 26.0% 和 25.3%。

临床怎么用

  • 在达罗他胺联合 ADT 和多西他赛治疗 mHSPC 时,可通过适当的多西他赛剂量调整和早期 G-CSF 支持来维持有效剂量并降低中性粒细胞减少风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We assessed the impact of granulocyte colony-stimulating factor (G-CSF) use and docetaxel relative dose intensity (RDI) on the safety profile of the ARASENS (NCT02799602) triplet regimen with darolutamide in patients with metastatic hormone-sensitive prostate cancer. METHODS: Patients were randomized to darolutamide 600 mg orally twice daily or placebo, with androgen deprivation therapy (ADT) and docetaxel. Baseline characteristics, G-CSF use, and safety were analyzed according to docetaxel RDI (≤85 % vs >85 %). RESULTS: Of 1273 patients with docetaxel RDI data (darolutamide n = 637; placebo n = 636), > 97 % received an efficacious dose of docetaxel (RDI >80 %). Patient demographics and baseline disease characteristics were generally similar between RDI subgroups; > 60 % of patients with RDI ≤ 85 % were from the Asia-Pacific region. Concomitant G-CSF, with/without docetaxel dose modification, was used in 42.4 % (darolutamide) and 44.6 % (placebo) of patients, mainly as secondary prophylaxis; 61.3 % (darolutamide) and 64.4 % (placebo) received both docetaxel dose modifications and G-CSF. Grade ≥ 3 treatment-emergent adverse events (TEAEs), grade ≥ 3 neutropenia, and grade ≥ 3 febrile neutropenia were higher with docetaxel RDI ≤ 85 %, but docetaxel discontinuation rates were similar between subgroups (RDI ≤85 %: darolutamide 7.2 %, placebo 10.8 %; RDI >85 %: darolutamide 8.1 %, placebo 10.5 %). TEAEs leading to docetaxel dose modification were more frequent with docetaxel RDI ≤ 85 % (darolutamide 92.8 %; placebo 97.3 %) versus RDI > 85 % (darolutamide 26.0 %; placebo 25.3 %). CONCLUSION: Appropriate docetaxel dose modifications and early G-CSF use allowed almost all patients to receive an efficacious dose of docetaxel in combination with darolutamide and ADT and may prevent neutropenic complications in patients receiving docetaxel. PRIOR PRESENTATION: Previously presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, San Francisco, CA.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ong M, Suzuki H, Smith M, et al. Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study. Eur J Cancer. 2026. PMID: 41655462. doi:10.1016/j.ejca.2026.116264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。